Nautilus Biotechnology Inc
NAUT
Company Profile
Business description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Contact
2701 Eastlake Avenue East
SeattleWA98102
USAT: +1 206 333-2001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124
Stocks News & Analysis
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
stocks
Coca-Cola earnings: Billion-dollar brands and consumer engagement remain growth priorities
Despite macro and geopolitical challenges, Coca-Cola managed to increase sales in line with its long-term target.
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,298.80 | 24.30 | -0.26% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,953.80 | 303.26 | 0.53% |
| NZX 50 Index | 13,524.09 | 16.81 | 0.12% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,050.00 | 12.00 | -0.13% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |